It is hypothesized that PF-05212377 (SAM-760) will reverse scopolamine induced cognitive impairments in healthy adults subjects.
Proof of mechanism
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Enrollment
38
Capsule, single dose, oral, 1 day
injectable subcutaneous formulation, single dose, 1 day
5 mg, PF-05212377, capsule, single dose, 1 day
Pfizer Investigational Site
Rennes, France
Groton Maze Learning Task (Total Errors); included in CogState Battery of Tests.
Time frame: Day 1 at 0, 5, 6, 7, 8, 10 and 12 hours of each period
Detection Task (Speed; included in CogState Test Battery)
Time frame: Day 1 at 0, 5, 6, 7, 8, 10 and 12 hours of each period
One Card Learning Task (Accuracy of performance; included in CogState Test Battery)
Time frame: Day 1 at 0, 5, 6, 7, 8, 10 and 12 hours of each period
Continuous Paired Associate Learning Task (Number of errors; included in CogState Test Battery)
Time frame: Day 1 at 0, 5, 6, 7, 8, 10 and 12 hours of each period
Bond-Lader Visual Analog Scales (included in CogState Test Battery)
Time frame: Day 1 at 0, 5, 6, 7, 8, 10 and 12 hours of each period
Identification Task (Speed; included in CogState Test Battery)
Time frame: Day 1 at 0, 5, 6, 7, 8, 10 and 12 hours of each period
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
injectable subcutaneous formulation, single dose, 1 day
20 mg, capsule PF-05212377, single dose, 1 day
injectable subcutaneous formulation, single dose, 1 day
60 mg PF-05212377, capsule, single dose, 1 day
injectable sub cutaneous formulation, single dose, 1 day
Tablet, 10mg, single dose, 1 day
injectable sub cutaneous formulation, single dose, 1 day